The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival time of 10-12 months. Clinically, these poor outcomes are attributed to several factors, including late stage at the time of diagnosis impeding resectability, as well as multi-drug resistance. Despite the high pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Principe, Daniel R., Underwood, Patrick W., Korc, Murray, Trevino, Jose G., Munshi, Hidayatullah G., Rana, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319847/
https://www.ncbi.nlm.nih.gov/pubmed/34336673
http://dx.doi.org/10.3389/fonc.2021.688377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319847/
https://www.ncbi.nlm.nih.gov/pubmed/34336673
http://dx.doi.org/10.3389/fonc.2021.688377

Ejemplares similares